Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03758105
Other study ID # RC17_0493
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date February 4, 2019
Est. completion date November 11, 2023

Study information

Verified date February 2023
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the transcranial direct current stimulation (tDCS) cost-utility in the depression therapy. This is a 3 years medico-economics study with 1 year follow-up period involving patients with 1 or 2 depression treatment(s) failed. Eligible subject will be randomized in 2 groups, usual care with tDCS cure (arm A) or only usual care (arm B).


Description:

Transcranial direct current stimulation is a non-invasive brain neuromodulation technique. tDCS can be a new therapy in depression. This study focuses on tDCS cost-utility-analysis. Each patient is following during 12 months. Patients are randomized in 2 arms. Arm A usual care with tDCS cure or arm B usual care without tDCS. Patient in arm A get a initial tDCS cure one week after randomization. If these patients are answering to the treatment, they can have a new cure in case of relapse. This new cure can start from the second month following initial treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 214
Est. completion date November 11, 2023
Est. primary completion date November 11, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Depression according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) with 1 or 2 failed antidepressant treatments for the current episode. - MADRS score superior or equal to 15. - Patient agreeing to participate in the study - Patient able to answer questionnaires and able to go at research center for follow-up visit. - Patient with social insurance Exclusion Criteria: - Electroconvulsive therapy or repetitive transcranial magnetic stimulation for current depressive episode. - Depressive episode with psychotic symptoms or mixed. - Schizophrenia or addiction to another substance than nicotine - Severe neurological disorder (like epilepsy, neurological affect, neurological disease) - Severe and / or progressive somatic pathology (leave to the investigator judgment) preventing from participation in the study. - tDCS specific contraindications (intracerebral metallic implant, pacemaker) - Pregnancy or breast feeding. - Woman of childbearing age without contraception (hormonal or with medical device). - Participation in another interventional clinical trial - legal protection - Persons incarcerated or in obligation of treatment / medical treatment order.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
tDCS associated with usual care
A tDCS cure will be given to the group "tDCS", one week after their randomization. This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current. Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks.
Usual care
Medication and psychotherapy as prescribed in usual care

Locations

Country Name City State
France CHU d'Angers Angers
France Clinique Mirambeau Anglet
France CHRU de Besançon Besançon
France Chu Clermont Ferrand Clermont-Ferrand
France CHU de Dijon Dijon
France Chu de Lyon Lyon
France Nantes University Hospital Nantes
France Aphp Hopital Saint Antoine Paris
France CH Henri Laborit (Poitiers) Poitiers
France Centre hospitalier Guillaume Regnier Rennes Rennes
France CH du Rouvray - Rouen Rouen
France CHU de Tours / CHRU de Tours Tours

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cost-utility ratio, according to collective perspective of tDCS use in depression compared to usual care without active tDCS. The utility will be measured by :
Quality Adjusted Life Year (QALYs) as estimated from responses to the Euroqol-5 Dimensions (EQ-5D) health-related quality of life questionnaire. The questionnaire focuses on 5 dimensions: mobility, personal autonomy, current activities, pain/discomfort and anxiety/depression. For each of these dimensions, 5 answers are possible.
The costs will be measured by the addition of the following costs:
Drugs dispensing via Health insurance database "National system of information of the French health insurance" (SNIIRAM), hospitalizations, work stoppages and care consumption collected in a declarative patient questionnaire.
12 months
Secondary Budget impact analysis of spreading the most efficient strategy for using tDCS Comparison of intervention costs on the study sample and projection of these costs over 5 years, from the health insurance and hospital perspectives 5 years
Secondary Response rate Response is defined as follows: decrease of the MADRS score by at least 50% compared to baseline score. MADRS stands for Montgomery-Asberg Depression Rating Scale. It is used to measure the severity of depressive episodes in patients with mood disorders. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A score from 0 to 6 being normal/symptom absent and a score >34 being severe depression. at baseline, at the end of each tDCS cure (for Arm A patients) through study completion (12 months) and at 12 months for all patients
Secondary Remission rate Remission rate is defined as follows: MADRS score < 10 (see detailed description of MADRS in outcome 3) 12 months
Secondary Relapse-free survival Number of patients with no relapse. Relapse is defined as follows: MADRS = 20 (see detailed description of MADRS in outcome 3) 12 months
Secondary MADRS score MADRS score (see detailed description of MADRS in outcome 3) At Baseline, one month, 2 months, 6 months and 12 months.
Secondary Beck Depression Inventory (BDI) score The BDI is 13-item multiple-choice self-report inventory, for measuring the severity of depression. The global score is an addition of each item's score and ranges from 0 (minimal depression) to 39 (severe depression). At Baseline, one month, 2 months, 6 months and 12 months.
Secondary Clinical Global Impression (CGI) score The Clinical Global Impression (CGI) rating scales are measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders. Each scale is rated from 0 to 7. 0 being the best level and 7 the worst level. At Baseline, one month, 2 months, 6 months and 12 months.
Secondary MOCA Score (Montreal Cognitive Assessment) Thirty items assessing multiple cognitive domains are contained in the MoCA: short-term memory (5 points); visuospatial abilities via clock drawing (3 points), and a cube copy task (1 point); executive functioning via an adaptation of Trail Making Test Part B (1 point), phonemic fluency (1 point), and verbal abstraction (2 points); attention, concentration, and working memory via target detection (1 point), serial subtraction (3 points), digits forward (1 point), and digits backward (1 point); language via confrontation naming with low-familiarity animals (3 points), and repetition of complex sentences (2 points); and orientation to time and place (6 points) At Baseline, one month, 2 months, 6 months and 12 months.
Secondary Adverse events linked to the medical treatment for depression Number and types of adverse events linked to the medical treatment for depression 12 months
Secondary Rate of suicide attempts number of suicide attempts per patient 12 months
Secondary Rate of suicides number of suicides 12 months
Secondary Treatment(s) switch(es) Number of treatment switches per patient At Baseline, one month, 2 months, 6 months and 12 months.
Secondary Treatment(s) dose increase Number of drug(s) dose(s) increases prescribed to the patient At Baseline, one month, 2 months, 6 months and 12 months.
Secondary Treatments combination(s) List of drugs (name) prescribed to the patient at Baseline, one month, 2 months, 6 months and 12 months.
Secondary Declarative drug compliance via the MARS (Medication Adherence Report Scale) MARS is the Medication Adherence Report Scale, including 10 questions, the global score ranges from 0 to 10, 0 corresponds to the worst drug compliance and 10 to an excellent drug compliance at baseline and at 12 months
Secondary Declarative drug compliance via the CRS (Clinician Rating Scale) CRS is the Clinician Rating Scale , including 7 questions, the global score ranges from 1 to 7, 7 being the worst level of drug compliance. at baseline and at 12 months
Secondary Total number of tDCS sessions total number of tDCS sessions per patient 12 months
Secondary Number of days between the successive tDCS cures Number of days between end of tDCS cure X and beginning of cure X+1, for each patient 12 months
Secondary Adverse events linked to tDCS Number and types of adverse events linked to the tDCS 12 months
Secondary Compliance with tDCS number of missed sessions over the number of planned sessions, per patient 12 months
Secondary Patient acceptability of the tDCS technique: Analog Visual Scale Analog Visual Scale of acceptability of the tDCS completed by the patient, ranging from 0 to 10. 0 being "not acceptable" and 10 being "totally acceptable" at the end of the first tDCS cure (up to one month)
Secondary professional status patient's professional status (active, unemployed, retired...) At baseline
Secondary Impact of the implementation of the tDCS on the organization of care The organizational impact of the tDCS will be evaluated from the point of view of doctors, nurse and patients: staff, equipment, maintenance, location and mobilization time of these resources, using a specific questionnaire 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A